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Abstract
A maladaptive shift from fat to carbohydrate (CHO) oxidation during exercise
is thought to underlie myopathy and exercise-induced rhabdomyolysis in
patients with fatty acid oxidation (FAO) disorders. We hypothesised that inges-
tion of a ketone ester (KE) drink prior to exercise could serve as an alternative
oxidative substrate supply to boost muscular ATP homeostasis. To establish a
rational basis for therapeutic use of KE supplementation in FAO, we tested this
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hypothesis in patients deficient in Very Long-Chain acyl-CoA Dehydrogenase
(VLCAD). Five patients (range 17-45 y; 4 M/1F) patients were included in an
investigator-initiated, randomised, blinded, placebo-controlled, 2-way cross-
over study. Patients drank either a KE + CHO mix or an isocaloric CHO equiv-
alent and performed 35 minutes upright cycling followed by 10 minutes supine
cycling inside a Magnetic Resonance scanner at individual maximal FAO work
rate (fatmax; approximately 40% VO2max). The protocol was repeated after a
1-week interval with the alternate drink. Primary outcome measures were
quadriceps phosphocreatine (PCr), Pi and pH dynamics during exercise and
recovery assayed by in vivo 31P-MR spectroscopy. Secondary outcomes
included plasma and muscle metabolites and respiratory gas exchange record-
ings. Ingestion of KE rapidly induced mild ketosis and increased muscle BHB
content. During exercise at FATMAX, VLCADD-specific plasma acylcarnitine
levels, quadriceps glycolytic intermediate levels and in vivo Pi/PCr ratio were
all lower in KE + CHO than CHO. These results provide a rational basis for
future clinical trials of synthetic ketone ester supplementation therapy in
patients with FAO disorders.
Trial registration: ClinicalTrials.gov. Protocol ID: NCT03531554; METC2014.492;
ABR51222.042.14.
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1 | INTRODUCTION
Very long-chain acyl-CoA dehydrogenase deficiency
(VLCADD) is an inborn error of fatty acid oxidation
(FAO) that is included in many newborn screening pro-
grams worldwide. Despite early diagnosis, the lack of
therapeutic options may cause patients to present with a
broad clinical spectrum, ranging from infant fatality to
exercise intolerance and elevated risk of exertional rhab-
domyolysis starting in childhood or adolescence.1-6 The
latter symptoms in patients with VLCADD have been
attributed to an inability of carbohydrate oxidation
(CHO) to fully compensate for the loss of mitochondrial
FAO capacity without the risk of glycogen depletion and
subsequent ATP depletion during prolonged exercise.7-9
We recently showed that this risk is aggravated by a
higher ATP cost of muscle contraction10 likely resulting
from the same adaptive phenotypic muscle remodelling
observed in a mouse model for FAO deficiency.9,11
The standard treatment for VLCADD patients has
been dietary restriction of long-chain triglycerides
(LCT) and supplementation of medium-chain triglyc-
erides (MCT) to bypass defective long-chain fatty acid
oxidation as well as boost production of ketone bod-
ies by the liver.5,6,12-14 However, this has proven to be
unsuccessful to prevent rhabdomyolysis and muscle-
related complaints. The same problems apply for
supplementation of triheptanoin, a 7-carbon fatty
acid.15,16 Instead, supplementation of ketone bodies
would be an attractive alternative dietary treatment
strategy.17
The ketone bodies acetoacetate (AcAc) and beta-
hydroxybutyrate (BHB) are readily taken up by all tis-
sues including cardiac and skeletal muscle, and, except
for liver, exclusively used as oxidative substrate.17-20
For example, studies in dogs have shown that the myo-
cardium switches almost completely from fat oxidation
to BHB oxidation upon infusion of the latter.20,21 More-
over, in vivo 31P magnetic resonance spectroscopy
recordings from the hearts of these dogs showed that
this substrate switch was associated with an energeti-
cally favourable change in myocardial concentration
ratio of inorganic phosphate (Pi) and phosphocreatine
(PCr).21 This observation confirmed a previous proposi-
tion that the thermodynamic efficiency of intracellular
energy transduction—that is, the transformation of
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chemical energy stored in oxidative substrates (CHO,
FFA, BHB) to Gibbs free energy stored in a highly non-
equilibrium cytoplasmic concentration ratio of ATP
and its hydrolysis products ADP and Pi22 — is higher
for BHB oxidation than for fat or CHO oxidation.23
Skeletal muscle in these dogs was likewise found to
switch completely to BHB oxidation, albeit that this
observation was made in sedated animals and not in
exercised state.20 Therapeutic use of BHB has been
described in multiple acyl-CoA dehydrogenase defi-
ciency (MADD), a mitochondrial disorder that also
involves impaired FAO, but with a more severe pheno-
type than fatty acid oxidation disorders (FAODs).24-26
The first described synthetic ketone ester (KE) was a
glycerol mono-ester of AcAc (“monoacetoacetin”) that
allows circumvention of any problem of salt-loading asso-
ciated with parenteral or enteral administration of com-
mon commercially available sodium salt preparations of
AcAc or BHB.27 The later synthesised (R,S)1,3-butanediol
AcAc esters18,19 produced mild ketosis in pigs lasting sev-
eral hours after enteral administration18,19 demonstrating
potential for clinical use in humans. Clarke and
coworkers first tested and confirmed the potential of syn-
thetic KE supplementation in healthy subjects using an
alternative KE28 and later showed in elite athletes that
mild ketosis resulted in leg muscle BHB uptake and gly-
cogen sparing during exercise.29
On basis of these considerations, we hypothesised that
single dose oral administration of KE prior to any exercise
may protect VLCADD and other FAOD patients from gly-
cogen depletion and rhabdomyolysis after exercise. How-
ever, the specific metabolic and physiological actions of
nutritional ketosis (NK) during exercise in humans have
only been tested in athletes,29 not in patients with a FAO
disorder. Therefore, prior to embarking on any long-term
clinical trial, a number of questions need to be answered
including: (a) is enteral delivery of the KE well tolerated
by patients; (b) does a single dose of KE induce mild NK
in blood with concomitant preservation of nor-
moglycaemia in VLCADD patients; (c) do muscles of
VLCADD patients take up and oxidise BHB during exer-
cise rather than CHO in the presence of mild NK?
2 | METHODS
2.1 | Patients
A single-centre, multi-location, randomised, blinded,
placebo-controlled, 2-way cross-over trial with 5 VLCADD
patients (median 22 years [range 17-45]; 4 M/1F) were
included. Diagnosis was confirmed by enzymatic analysis
of lymphocytes and fibroblasts in combination with bi-
allelic mutations in the ACADVL gene (OMIM 609575).
None of the patients had a history of abnormal cardiopul-
monary function. Baseline characteristics and results of
enzymatic and genetic studies in the five VLCADD
patients are presented in Tables S1 and S2.
The study was approved by the medical ethics com-
mittee of the University Medical Centre Groningen
(METC 14-492). All patients provided written informed
consent for participation in this study. All procedures
followed were in accordance with the ethical standards of
the responsible committee on human experimentation
(institutional and national) and with the Helsinki Decla-
ration of 1975, as revised in 2000.
2.2 | Study design
The study consisted of three exercise tests separated by at
least 1 week (Figure 1). First, patients performed a graded
cardio-pulmonary exercise test (CPET)30 on an upright
bicycle ergometer at location AMC. From the results of
this test, the workload corresponding to maximal bodily
fat oxidation (FATMAX) was determined for each sub-
ject. Details on materials and methods of this baseline
visit are available as supplemental material. Exercise tests
two and three including in-magnet exercise were per-
formed at location UMCG. Thirty minutes prior to exer-
cise patients received either a drink containing
395 mg/kg of ketone ester (KE) + 54 g of dextrose or an
isocaloric carbohydrate (CHO) drink containing only
dextrose. Details on randomisation, blinding, drink prep-
aration, and dietary standardisation are available as sup-
plemental material.
2.3 | Primary and secondary outcome
Primary outcome measures were quadriceps phosphocrea-
tine (PCr), Pi and pH dynamics during exercise and recov-
ery assayed by in vivo 31P-MR spectroscopy. Secondary
outcomes were whole blood BHB and glucose levels,
plasma lactate, creatine kinase, free fatty acids, insulin,
and acylcarnitine species. Muscle metabolites (glycolysis
and TCA intermediates and acylcarnitine species), respira-
tory gas exchange recordings and subjective exertion and
physical complaints scores were also secondary outcomes.
2.4 | Endurance exercise test - second
and third test day
The exercise protocol for the second and third test day
was identical except for drink content that was allocated
BLEEKER ET AL. 3
by randomisation. At t = 0 the patient consumed the test
drink. At t = 30 minutes the patient initiated a
35-minute exercise bout on an upright cycle ergometer
(Lode Corival, Lode BV, Groningen, the Netherlands) at
individual FATMAX. Pedalling frequency was
maintained between 60 and 80 rpm. After completion of
the upright exercise bout, the patient was fitted with
bicycle race shoes equipped with binding cleats and
transported to the MR scanner in a wheelchair for a final
10 minutes supine cycling exercise bout inside the MR-
scanner. Patients received the reverse drink during the
third test day.
2.5 | Blood sampling
At the start of days two and three of the protocol, a
venous catheter was inserted percutaneously into an
antecubital vein of the patient for blood sampling. Glu-
cose and D-BHB were directly measured on-site in
whole blood (Freestyle Precision, Abbot Diabetes Care,
Alameda, California; Glucomen LX plus, Menarini
Diagnostics, Florence, Italy). Blood samples were
immediately stored on ice. At the end of the protocol,
all samples were transferred to the biochemistry lab in
another building, centrifuged (1200 rcf at 10 minutes)
and stored at −80C until further analysis. FFA were
analysed by an enzymatic colorimetric method (NEFA
C test kit [Wako Chemicals, Neuss, Germany]) as
described previously.31
2.6 | Pulmonary gas exchange
recordings
Dynamic respiratory gas collection was performed on
days two and three of the protocol. Patients were fitted
with a mask and heart rate monitor (K4b2, Cosmed,
Rome, Italy) and seated on the upright cycle ergometer.
First, baseline recordings were collected for 10 minutes.
During stationary upright bicycling at individual
FATMAX respiratory gas samples were collected at
t = 30, 40, 50, and 60 minutes. The duration of respira-
tory gas sampling was 2 minutes for each time point.
Respiratory gas sampling was not possible during cycling
inside the MR scanner.
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FIGURE 1 Study protocol and effects of dietary substrates during exercise on tolerability and cardiopulmonary exercise testing. A,
Studyprotocol; B, Maximum scores of complaints during study protocol reported by patients; C, Concentration of creatine kinase in plasma
after CHO (blue) or KE + CHO (red) ingestion; D, Subjective exertion score reported by patients after CHO (blue) or KE + CHO (red)
ingestion; E and F, Heart rate (E) and respiratory exchange ratio measured during upright bicycling bout of protocol after CHO (blue) or KE
+ CHO (red) ingestion. N = 5, data are presented as mean ± SEM. Differences between groups were analysed with two-way ANOVA for
repeated measures with Bonferroni post-hoc analysis
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2.7 | Muscle biopsy
Muscle tissue was collected from patients 2-5 using per-
cutaneous needle biopsies from the lower third of the
vastus lateralis muscle (Bard Monopty, Bard Biopsy,
Tempe, Arizona) as described.29 No muscle biopsies were
collected from patient 1. Biopsy samples were obtained
from fresh incisions prior to and immediately following
the 35 minutes exercise bout, respectively. Tissue was fro-
zen immediately in liquid nitrogen and stored at −80C
until further analysis.
2.8 | In vivo 31P MR spectroscopy
In vivo 31P MR spectra were acquired from the vastus
lateralis muscle using a 3 Tesla Achieva MR scanner
(Philips Healthcare, Best, the Netherlands). The exact
positioning of the MR-compatible bicycle ergometer
inside the scanner tube and length of the hand straps
were customised to the physical dimensions of the
patient prior to the start of the study protocol on days
two and three. Patients also performed a short bout of
unloaded exercise to familiarise themselves with the MR
study protocol. After 65 minutes of the study, a 6 cm sur-
face coil (Philips Healthcare) was fastened over the vastus
lateralis muscle of the leg that had not been used for
muscle biopsy prior to and immediately after the preced-
ing upright bicycle exercise bout. Scout MRI scans were
acquired for image-based shimming of the magnet.
Dynamic 31P MR spectra during exercise and recovery
were acquired with 8 seconds time resolution using an
adiabatic half-passage pulse (NSA 2, TR 4000) according
to methods described elsewhere.10 The desired pedalling
frequency (target setting: 80 rpm) was set by a metro-
nome audible over the in-magnet speaker system.32 Syn-
chronisation of MRS data acquisition with pedalling
during exercise was performed using custom-built
Labview software (National Instruments, Roscoe, Illinois)
as described elsewhere.10 Details on processing of 31P
MRS data are available as supplemental materials.
2.9 | Acylcarnitine analysis
Plasma acylcarnitines were analysed using electrospray
tandem mass spectrometry as described previously.33
2.10 | Muscle metabolomics
Muscle samples were freeze dried, homogenised and
approximately 1 mg of dry weight muscle tissue was
prepared for mass spectrometry. After addition of inter-










phosphate, and guanosine-15N5-triphosphate (5 μM)),
MilliQ was added to a total volume of 500 μL. Subse-
quently 500 μL Methanol and 1 mL chloroform were
added. Samples were vortexed, sonicated, and centrifuged
for 5 minutes at 14 000 rpm at 4C. The “polar” top layer
was dried in a vacuum concentrator in a new tube. Dried
samples were dissolved in 100 μL methanol/water (6/4;
v/v). A Thermo Scientific ultra-high-pressure liquid chro-
matography system (Waltman, Massachusetts) coupled to
Thermo Q Exactive (Plus) Orbitrap mass spectrometer
(Waltman, Massachusetts) was used for the analysis as
described previously.34 Values were depicted as the ratio of
peak area over internal standard (PA) and normalised for
the sum of ATP + ADP + AMP (TAN) per sample.
2.11 | Statistical analysis
Prism 6 software (GraphPad Software, Inc., La Jolla, Cali-
fornia) was used for statistical analysis. Results are
expressed as means ± SEM and significance were
established a priori at P < .05. For plasma metabolites,
heart rate, RER, Borg score a single paired t test was per-
formed for every time point and a two-way ANOVA for
repeated measures with Bonferroni post-hoc analysis
for differences between test drinks throughout the proto-
col. For muscle metabolites, two-way ANOVA with
Bonferroni post-hoc analysis for the effect of both treat-
ment and exercise and paired t tests to compare the effect
of exercise within treatment. For statistical differences in
the 31P-MRS data, a two-tailed paired student's t test
was used.
3 | RESULTS
3.1 | Ingestion of the KE drink was
tolerated by all patients
On visits 2 and 3, patients ingested either the blinded iso-
caloric KE + CHO or CHO drink, (Figure 1A). Both
drinks were taste-matched (see Section 2) and were toler-
ated by all patients. Two patients complained of mild to
moderate transient nausea following ingestion of the
blinded KE drink (Figure 1B), with one patient regurgi-
tating the KE drink after which the study was discon-
tinued and repeated on a different day. These patients
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also reported a mild sensation of heart burn and bloating
during upright bicycling. Lower intestinal complaints (eg,
intestinal cramps, diarrhoea) were not reported. One
patient reported moderate muscle cramps during upright
bicycling, but was able to complete the entire protocol.
The total of 45 minutes of submaximal exercise per-
formed during these visits did not result in any muscle
damage as evidenced by lack of any significant increase
in individual basal plasma CK levels (Figure 1C). Subjec-
tive exertional (Borg) scores during bicycling at Wfatmax
increased from 8 to 12 during upright bicycling (maxi-
mum: 20; Figure 1D). Heart rate increased moderately in
both arms of the study (Figure 1F). The respiratory quo-
tient (RQ) was typically higher in the CHO arm com-
pared to KE + CHO (Figure 1G). In both arms, however,
values remained close to 0.9.
3.2 | Ingestion of the KE drink results in
mild ketosis while blood glucose levels
remain normal
Within 30 minutes of ingestion of the KE drink
(KE + CHO) BHB concentrations in blood increased to
2.0 ± 0.2 mmol/L (Figure 2A). BHB concentrations
remained significantly higher compared to values after
isocaloric CHO ingestion for the entire protocol
(P = .0002 for the effect of intervention, P < .0001 for
time and P < .0001 for intervention × time). During the
second bout of cycling exercise inside the scanner in the
KE arm, BHB blood concentration significantly dropped
1.4-fold (P < .05). Peak blood BHB concentrations in the
patients were comparable to previous studies of NK after
KE supplementation in healthy individuals.29,35,36 Four
hours after ingestion of the KE drink, BHB blood concen-
trations had almost dropped to baseline (Figure 2A).
Blood glucose in both arms of the study remained within
normal values during the entire protocol (KE 5.7 ± 0.4 vs
CHO 6.4 ± 0.7 mmol/L, respectively; mean ± SD)
(Figure 2B). During the second bout of cycling exercise
inside the scanner in the CHO arm, but not the KE
+ CHO arm, blood glucose dropped significantly from an
average value of 7.0 to 5.0 mmol/L (P < .05) (Figure 2B).
Plasma insulin levels increased transiently in response to
each drink and returned to basal levels during the first
bout of exercise in all patients (Figure 2C). Basal and
peak insulin concentrations in patients 2-5 were similar,
but in patient 1 these concentrations were one order of
magnitude higher. At the end of exercise as well as
3 hours after ingestion of the drink, plasma insulin in this
patient were 2-fold lower compared to baseline after
ingestion of the KE + CHO drink, but remained similar
after ingestion of the CHO drink (Figure 2C). Plasma
lactate levels during the bout of upright cycling remained
between 1 and 2 mmol/L in both arms. In the KE + CHO
armplasma lactate concentrations tended to be 1.3-fold lower
at the end of exercise than at onset (P= .07; Figure 2D).
3.3 | Ingestion of the KE drink reduces
plasma long-chain acylcarnitines
NK reduced the total concentration of long-chain
acylcarnitines in plasma at rest, including the VLCADD
specific disease marker [35] C14:1-carnitine (C14:1
carnitine P = .06 for the effect of intervention, P = .006 for
time, and P = .09 for intervention × time; C14 + C16
+ C18 carnitine P = .09 for the effect of intervention,
P = .0001 for time, and P = .61 for intervention × time)
(Figure 2E-F) suggesting FAO in heart, liver, and kidney
was reduced compared to CHO. Plasma long-chain
acylcarnitine concentrations during NK remained lower
than with CHO for 4 hours including during exercise.
Plasma concentrations of free fatty acids (FFA) fell after
both KE + CHO and CHO ingestion (P = .3 for the effect of
intervention, P = .001 for time, and P = .5 for inter-
vention × time) (Figure 2G).The plasma concentration of
acetylcarnitine during NK increased compared to CHO
(P = .05 for the effect of intervention, P = .0001 for time,
P = .0002 for intervention × time) (Figure 2H).
3.4 | Ingestion of the KE drink results in
muscular BHB uptake and appears to blunt
glycolysis
Next, we analysed the impact of NK during exercise on
intramuscular oxidative metabolism by performing semi-
targeted metabolomics in muscle biopsies. Specifically,
we analysed muscle samples obtained from patients 2-5.
Because of highly unfavourable muscle-to-fat body com-
position ratio of patient #1 no muscle biopsy was taken
from this patient. To control for variation in actual biopsy
tissue composition between patients all results of muscle
metabolomics analysis were normalised to total adeno-
sine nucleotides (TAN): ATP + ADP + AMP. The muscle
metabolomics results first showed that BHB was taken
up by muscle during NK (Figure 3A). This confirmed that
BHB was available as oxidative substrate to maintain
intramuscular energy balance during exercise. Secondly,
NK tended to blunt the increase of intramuscular glyco-
lytic intermediates during exercise seen after CHO inges-
tion (Figure 3B). Specifically, the sum of intramuscular
glycolytic intermediates normalised to TAN remained
unchanged in NK but increased in three out of four
patients after ingestion of the CHO drink (Figure 3B).
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This seems to be attributed to the change in fructose-1,-
6-bisphosphate (Figure 3C). Qualitatively different trends in
the metabolic response to exercise for the CHO vs KE
+ CHO arms for other metabolites including the sum of tri-
cyclic acid (TCA) cycle intermediates (Figure 3D) could not
be statistically objectified. However, individual trends were
in agreement with the notion that NK blunted intramuscu-
lar glycolysis during exercise. No significant differential
effect of NK vs CHO ingestion on intramuscular fat oxida-
tion was found on basis of metabolomics analysis of long-,
medium-, and short-chain acylcarnitines in biopsies
(Figure 3E-P).
3.5 | Ingestion of the KE drink improves
muscular energy balance during exercise
Lastly, we conducted in vivo MR image measurements
on the leg muscles to investigate if NK during exercise
caused a similar favourable change in the intramuscular
concentration ratio of inorganic phosphate (Pi) and phos-
phocreatine (PCr) as previously reported in dogs infused
with BHB.21 Scout T1-weighted MR images of the legs
confirmed that patients #2-5 but not patient #1 had nor-
mal muscle-to-fat ratio (Figure 4A). In vivo 31P-MR
spectra obtained during stationary cycling exercise at a
workload equivalent to FATMAX in each patient were of
adequate quality to estimate the in vivo intramuscular Pi
and PCr concentrations in working leg muscle
(Figure 4B). Quantitative analysis of the spectra showed
that in patients 3, 4, and 5 the Pi/PCr ratio in exercising
leg muscle during NK was 40% % lower than in the CHO
arm at one and the same normalised workload
(Figure 4C). In patient 1 no change in Pi/PCr ratio was
observed (Figure 4C). In patient 2, 31P-MRS data
recorded during the KE arm were lost due to technical
problems. Post-exercise, the rate of oxidative metabolic
recovery indexed by the time constant of PCr recovery to
basal level was identical for both arms (Figure 4D).
4 | DISCUSSION
Our study shows that clinical use of a BHB-
(R) 1,3-butanediol ketone ester in patients with VLCADD
has significant potential to serve as a treatment. First, the
tolerability of this particular synthetic ketone ester was
acceptable. Secondly, ingestion of the ester resulted in all
patients rapidly and reproducibly in mild ketosis in blood
as well as significant BHB uptake by skeletal muscle,
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(E) (F) (G) (H)
FIGURE 2 Effects of dietary substrates during exercise on plasma metabolites in VLCADD patients. A-D, Concentration of beta-
hydroxybutyrate (A) glucose (B) in whole blood, insulin (C) and lactate (D) in plasma after CHO or KE + CHO ingestion. E-H, Fold change
from baseline concentration of C14:1-carnitine (C), sum of C14 + C16 + C18-carnitine (D), free fatty acids (E) and C2-carnitine (F) in
plasma. In A, C-F n = 5 for CHO and KE + CHO. In B n = 5 for KE + CHO, n = 5 for CHO in t = 0 and 3 hours after exercise, n = 4 for
CHO in t = 30-85. Data are presented as mean ± SEM. Differences between groups were analysed with two-way ANOVA for repeated
measures with Bonferroni post-hoc analysis. The red bar in graph A represents the differences between t = 75 and t = 85 for KE + CHO
analysed with paired –t test. The blue bar in graph B represents the difference between t = 75 and t = 85 for CHO analysed with paired –t
test. **** indicates P value <.001, *** indicates P value <.001, ** indicates P value <.01, and * indicates P value <.05
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while blood glucose levels remained within normal range
during the entire study protocol. The level of ketosis in
blood was in close agreement with previous findings in
healthy individuals.29,35,36 Thirdly, plasma concentrations
of long-chain acylcarnitines, disease-specific biomarkers
that are hallmarks of a FAO disorder, were significantly
lower during exercise after use of the ketone ester.
Finally, in vivo we observed that that the Pi/PCr ratio in
leg muscle during exercise at FATMAX workload was
lower in the majority of patients after use of the ketone
ester. This indicates that intramuscular energy balance
during exercise improved after use of the ketone ester.
(A) (B) (C) (D)
(E) (F) (G) (H)
(I) (J) (K) (L)





















































































































































































































































































































































































































































































































































































































































































































































































































































FIGURE 3 Effects of dietary substrates and exercise on muscle glucose and fat metabolism in VLCADD patients before and after
exercise. A, Intramuscular concentrations of beta-hydroxybutyrate before and after exercise after ingestion of CHO or KE + CHO. B, Sum of
intramuscular concentrations of glycolytic intermediates (Hexose-P, Fructose-1,6-diphosphate, Glyceraldehyde-3P, 1,3-Diphosphoglyceric
acid, 2-/3-Phosphoglyceric acid and Phosphoenolpyruvate) before and after exercise after ingestion of CHO or KE + CHO. C, Intramuscular
concentrations of fructose 1,6-diphosphate before and after exercise after ingestion of CHO or KE + CHO. D, Sum of intramuscular
concentrations of tricyclic acid cycle intermediates (citrate/isocitrate, α-ketoglutarate, succinate, fumarate, malate) before and after exercise
after ingestion of carbohydrates or ketone ester. E-P, Intramuscular concentrations of acylcarnitine species before and after exercise after
ingestion of CHO or KE + CHO. Values on the Y-axis are the ratio of peak area over internal standard (PA), corrected for the total
adenosine nucleotides (ATP + ADP + AMP) (TAN), per sample. Error bars are mean ± SD. N = 4 for all conditions. ** = P < .01 with
2 way ANOVA
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The major complaint concerning the tolerability was
nausea related to the large volume of the drink in combi-
nation with the acrid taste of the ester. This potential bar-
rier to clinical use can, however, be overcome easily by
adopting the shot-like bolus ingestion strategy of the
undiluted KE followed by a big volume of a tasty CHO
drink.
Various findings in this study suggest that BHB in the
bloodstream was indeed a major source of oxidative
substrate in VLCADD muscle during exercise. As such,
this study shows that nutritional ketosis by acute inges-
tion of KE is a viable new therapeutic option in clinical
management of FAO disorders. Firstly, in the KE + CHO
arm blood BHB significantly dropped during exercise. In
contrast, in the CHO arm blood glucose dropped during
exercise, suggesting that these substrates were oxidised
during exercise. Secondly, in muscle, glycolytic flux was
upregulated in the CHO arm, but not in the KE + CHO
FIGURE 4 Effects of dietary substrates on in vivo muscle energetics during and after cycling in VLCADD patients. A, Transversal
T1-weighted MR images of the right upper leg of patients #4 (A.1) and #1 (A.2). Subjects were positioned feet-first. The slightly flattened left
side of the thigh image indicates the position of the 31P surface coil overlying the m. vastus lateralis. Note the large diameter of the
subcutaneous fat layer surrounding the thigh muscles in female patient #1. B, in vivo 31P Magnetic Resonance spectra of the vastus lateralis
muscle of patient ID4 recorded during stationary exercise at individual FATMAX workload after either CHO (top trace) or KE + CHO
ingestion (bottom trace), respectively. ATP, adenosine triphosphate; Pi, inorganic phosphate; PCr, phosphocreatine. C and D, Mean in vivo
concentration ratio of inorganic phosphate (Pi) and phosphocreatine (PCr) during stationary exercise (C) and mean recovery time constant
(D) of the vastus lateralis muscle of 4 VLCADD patients after CHO vs KE + CHO ingestion, respectively. * indicates P value <.05; two tailed
paired t test. Data are presented as mean ± SEM
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arm as evidenced by our metabolomics results. The ten-
dency of plasma lactate to drop during exercise in the
KE + CHO arm, but not the CHO arm, agrees with this
scenario. Also, our finding of a 1.2-fold higher rise of
plasma acetylcarnitine (C2) during exercise in the KE
+ CHO arm compared to CHO arm fits with elevated oxi-
dative substrate availability during NK.23,37 In vivo, we
observed that the intramuscular energy balance during
exercise in the majority of patients improved in the KE
+ CHO arm compared to CHO analogous to previous
findings on the impact of BHB vs CHO infusion on intra-
cellular energy balance in working cardiac muscle.21
With respect to the magnitude of change in in vivo
Pi/PCr ratio that we observed in leg muscle of VLCADD
patients, it is unlikely that this was entirely due to the
previously demonstrated favourable thermodynamic
effect of BHB oxidation on mitochondrial energy trans-
duction.21,23 Specifically, Kim and coworkers found a
10% improvement in in vivo myocardial Pi/PCr ratio in
dogs infused with BHB vs CHO21 whereas we observed a
40% improvement in in vivo Pi/PCr ratio in the working
quadriceps muscle (Figure 4C). Less recruitment of fast-
twitch motor units of the quadriceps muscle to perform
the voluntary exercise task in the NK arm vs the CHO
arm would explain this finding. In this light, it is of inter-
est to note that we previously found evidence that the
quadriceps muscle of VLCADD patients exercising at
individual FATMAX workload recruits more fast-twitch
motor units than healthy individuals to deliver the
desired power-output.10 As such, these findings would
suggest that mild NK during exercise in VLCADD
patients not only impacts metabolism but also mechani-
cal performance of oxidative muscle fibres. This hypothe-
sis remains to be tested. In the only available study of the
effect of mild NK on physical performance, a minor but
significant improvement was, however, found in elite
athletes performing a maximal test (distance covered dur-
ing a 30-minute time trial).29
Long-chain acylcarnitines are disease-specific bio-
markers for FAO disorders, for VLCADD in particular
C14:1-carnitine.38 Intramitochondrial accumulation of
long-chain acylcarnitines due to a defective FAO can
have detrimental effects on cell function.39 Therefore, an
additional beneficial effect of supplying patients with
FAO disorders with an alternative oxidative substrate in
the form of a KE drink, is that accumulation of these
potentially toxic metabolites during exercise may be
averted. Indeed, accumulation of plasma C14:1-carnitine
during exercise was almost halved in the KE + CHO arm
compared to CHO.
The overall outcome of the present study in VLCADD
patients suggests that a rational basis exists for the thera-
peutic use of synthetic KE supplementation prior to
exercise in patients with a defective FAO. This is espe-
cially important considering the lack of satisfactory thera-
peutic options for these patients. Currently, MCT is
widely used as an alternative oxidative substrate in
patients, MCT ingestion prior to exercise induces mild
ketosis, albeit at a significantly lower level (0.5-1 mM)40
than found in the present study after a single-dose KE
ingestion. Moreover, the medium-chain FA may serve as
substrate for fatty acid synthesis by chain elongation, as
was observed in FAO defective mice and patients' fibro-
blasts.41-44 As such, the efficacy of MCT supplementation
to provide alternative oxidative substrate for ATP synthe-
sis in FAOD patients is questionable and is proven to be
insufficient to prevent rhabdomyolysis completely in
patients.15,45,46 The problem of rhabdomyolysis is also
not resolved by triheptanoin treatment.15,16 In the pre-
sent study, one patient (subject 5) used MCT supplemen-
tation. The outcome in this particular patient did not
differ significantly from the other patients. It could be
interesting to test the potential complementary effect of
MCT and KE or KE and triheptanoin supplementation
prior to exercise in future studies.
The potential benefits of synthetic KE supplementation
are probably not limited to FAO disorders such as
VLCADD, but might very well be relevant for other inborn
errors of metabolism, such as MADD patients that suffer
from a defect in the reoxidation of all acyl-CoA dehydroge-
nases and can therefore not oxidise MCT or triheptanoin.
Ketone salt supplementation is the only treatment option
in these patients, but long-term use comes with adverse
effects and alternative forms such as ketone acids do not
seem to have a clinical benefit.47,48 Inborn errors of metab-
olism that are treated with a ketogenic diet include glucose
transporter type 1 (GLUT1) deficiency and pyruvate dehy-
drogenase complex (PDHc) deficiency49 which may also
benefit from KE supplementation.
5 | CONCLUSION
The results of the studies described in this paper provide
strong evidence in favour of KE supplementation prior to
exercise in patients with defective FAO at the level of
VLCAD. Future studies should determine the clinical
and therapeutic utility of NK in VLCADD and other met-
abolic myopathies.
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